GLP-1
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association’s 79th Scientific Sessions in San Francisco this week.
Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.
“Over the past few years there has been a good amount of information presented at ADA. This year though, with all of the data presented, this was the most exciting year,” Todd Hobbs, U.S. chief medical officer of Novo Nordisk, told BioSpace in an exclusive interview.
Despite very positive results, the company’s shares were down 1.5% in premarket trading today. Vamil Divan, an analyst with Credite Suisse, wrote in a note to investors, that results “were fairly consistent across various patient subgroups and are clearly positive” for this class of drug, but “we believe investors may have been hoping for greater risk reduction.”
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
Adocia announces the initiation of a Phase 1b study of ADO09, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine.
Breakthrough in industrial large-scale manufacturing of well-defined biomedical fiber-based scaffolds for a wide variety of medical applications
The FDA extended the indication for Gattex to pediatric patients one year of age and older with short bowel syndrome.
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
PRESS RELEASES